Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Vaxzevria is highly effective after one dose against severe disease or hospitalisation caused by Beta and Delta variants of concern

07/23/2021 | 04:08am EDT
PUBLISHED23 July 2021
23 July 2021 09:00 BST
Real-world data from Canada showed 82% and 87% effectiveness after one dose against hospitalisation or death caused by Beta/Gamma and Delta variants respectively

Results from the Canadian Immunization Research Network (CIRN) with support from Public Health Agency of Canada and the Canadian Institutes of Health Research, published as a pre-print, demonstrated one dose of Vaxzevria was 82% effective against hospitalisation or death caused by the Beta/Gamma variants of the SARS-CoV-2 virus. The vaccine also showed a high level of effectiveness against the Delta (B.617.2, 'Indian') and Alpha (B.1.1.7, 'Kent') variants with an 87% and 90% reduction of hospitalisations or deaths respectively.1 The effectiveness of Vaxzevria after one dose against hospitalisation or death was similar to that of other vaccines tested in the study. Follow-up time was not sufficient to report on effectiveness of Vaxzevria after two doses, other studies have shown an increased effectiveness following the indicated two dose schedule.

Vaxzevria was effective against milder symptomatic disease although, given that data was only reported after a first dose instead of the indicated two dose schedule where efficacy is known to be enhanced in this disease setting,2 the efficacy was lower than against severe disease. Vaccine effectiveness against any symptomatic disease was 50% against the Beta/Gamma variants, and 70% and 72% against the Delta and Alpha variants, respectively.

A Phase I/II trial carried out by the University of Oxford and University of the Witwatersrand in January, had shown limited efficacy against mild disease primarily due to the Beta variant. It was unable to properly ascertain vaccine efficacy against severe disease including hospitalisation and death given that subjects were predominantly young, healthy adults who experienced mild disease only.3

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: 'With different variants threatening to disrupt our route out of the pandemic, this real-world evidence shows that Vaxzevria, along with other vaccines used in Canada, provides a high level of protection against the most serious forms of the disease, even after just one shot. It is essential that we continue to protect as many people as possible in all corners of the world in order to get ahead of this deadly virus.'

The analysis included 69,533 individuals who tested positive for SARS-CoV-2 during December 2020 to May 2021 in Ontario, Canada; with 28,705 (6.8%) positive for non-variants of concern SARS-CoV-2 and 40,828 (9.7%) positive for a variant of concern.

Vaxzevria, formerly AZD1222
Vaxzevria was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

The vaccine has been granted a conditional marketing authorisation or emergency use in more than 80 countries across six continents. More than 700 million doses of COVID-19 Vaccine AstraZeneca have been supplied to 170 countries worldwide, including more than 100 countries through the COVAX Facility.

AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

References

1. Nasreen S, (2021) Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. MedRxiv Online: https://www.medrxiv.org/content/10.1101/2021.06.28.21259420v2

2. Voysey, M, et al., (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397: 99-111. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext

3. Madhi, SA, et al., (2021) Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. New England Journal of Medicine, 384: 1885-98.

tags
  • Corporate and financial

Disclaimer

AstraZeneca plc published this content on 23 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 July 2021 08:07:07 UTC.


ę Publicnow 2021
All news about ASTRAZENECA PLC
02:21aASTRAZENECA : invests in Imperial's self-amplifying RNA technology with eye on future drug..
RE
02:12aASTRAZENECA : to discover and develop self-amplifying RNA therapeutics in new collaboratio..
PU
09/22ASTRAZENECA : Japan doubles COVID-19 vaccine donation pledge to 60 mln doses
RE
09/22ASTRAZENECA : Brazil regulator says adolescent death unrelated to Pfizer shot
RE
09/22MODERNA : Canada paused COVID-19 vaccine deliveries as supply far exceeds demand
AQ
09/22ASTRAZENECA : Anger, confusion spread over UK's new COVID travel rules
AQ
09/22PFIZER : COVID-19 Vaccine Elicits Strong Immune Response As Second Dose, Thailand Study Sa..
MT
09/22SINOVAC BIOTECH : Thailand delays plan to re-open cities to tourists until November
RE
09/22India's Serum Institute to invest $68 mln in UK vaccine maker Oxford Biomedica
RE
09/22ASTRAZENECA : MEDIA-UK govt approves Covishield as qualified vaccine for travel - Mint
RE
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 401 M - -
Net income 2021 5 006 M - -
Net Debt 2021 24 250 M - -
P/E ratio 2021 32,8x
Yield 2021 2,40%
Capitalization 182 B 182 B -
EV / Sales 2021 5,82x
EV / Sales 2022 4,72x
Nbr of Employees 76 100
Free-Float 96,3%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 117,33 $
Average target price 136,24 $
Spread / Average Target 16,1%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC17.65%182 344
JOHNSON & JOHNSON4.16%433 122
ROCHE HOLDING AG9.82%321 584
PFIZER, INC.19.32%246 246
NOVO NORDISK A/S52.07%234 070
ELI LILLY AND COMPANY35.22%208 668